Coagulation in colorectal cancer

Coagulation in colorectal cancer - the CoCo study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33373

Enrollment

300

Registered

2009-08-31

Start date

2009-03-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer malignancy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: colorectal cancer, any stage, not yet treated before

Exclusion criteria

Exclusion criteria: second primary tumor, except basal cell carcinoma

Design outcomes

Primary

Measure	Time frame
Primary study endpoint is the association between tissue factor positive microparticles level in colorectal cancer patients and time to progression.	—

Secondary

Measure	Time frame
The association between other procoagulant markers (thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and time to progression. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and the occurrence of a VTE. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and disease stage. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and the use of chemotherapy. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and the use of bevacizumab.	—

Measure

Time frame

The association between other procoagulant markers (thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and time to progression. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and the occurrence of a VTE. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and disease stage. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and the use of chemotherapy. The association between procoagulant markers (tissue factor positive microparticles, thrombomodulin, von Willebrand factor, PAP-complex, PAI-1, P-selectin, thrombospondin 1, tissue factor positive microparticles, tissue factor, cancer procoagulant, VEGF, thrombin generation, d-dimer) and the use of bevacizumab.

—

Countries

Netherlands

Outcome results